- Home
- HPH vs CGEN Comparison
HPH vs CGEN Comparison
Compare HPH & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPH
- CGEN
- Stock Information
- Founded
- HPH 2010
- CGEN 1993
- Country
- HPH China
- CGEN Israel
- Employees
- HPH N/A
- CGEN N/A
- Industry
- HPH
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HPH
- CGEN Health Care
- Exchange
- HPH NYSE
- CGEN Nasdaq
- Market Cap
- HPH 137.1M
- CGEN 142.8M
- IPO Year
- HPH 2019
- CGEN 2000
- Fundamental
- Price
- HPH $0.27
- CGEN $1.60
- Analyst Decision
- HPH
- CGEN Strong Buy
- Analyst Count
- HPH 0
- CGEN 2
- Target Price
- HPH N/A
- CGEN $4.00
- AVG Volume (30 Days)
- HPH 86.6K
- CGEN 445.1K
- Earning Date
- HPH 01-01-0001
- CGEN 11-12-2024
- Dividend Yield
- HPH N/A
- CGEN N/A
- EPS Growth
- HPH N/A
- CGEN N/A
- EPS
- HPH N/A
- CGEN 0.02
- Revenue
- HPH $286,996,105.00
- CGEN $59,852,000.00
- Revenue This Year
- HPH N/A
- CGEN $57.27
- Revenue Next Year
- HPH N/A
- CGEN N/A
- P/E Ratio
- HPH N/A
- CGEN $88.75
- Revenue Growth
- HPH 1722.42
- CGEN 698.03
- 52 Week Low
- HPH $0.26
- CGEN $1.35
- 52 Week High
- HPH $10.06
- CGEN $3.03
- Technical
- Relative Strength Index (RSI)
- HPH 28.85
- CGEN 51.01
- Support Level
- HPH $0.26
- CGEN $1.55
- Resistance Level
- HPH $0.29
- CGEN $1.68
- Average True Range (ATR)
- HPH 0.02
- CGEN 0.08
- MACD
- HPH 0.01
- CGEN 0.01
- Stochastic Oscillator
- HPH 5.00
- CGEN 52.17
About HPH HIGHEST PERFORMANCE HLDGS INC
Highest Performances Holdings Inc is a financial technology service group based on family financial asset allocation. It focuses on providing personalized wealth management services for emerging middle-class and affluent families, comprehensive support services for financial planners, and diversified financial services for institutional clients.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.